Laurus Labs

LAURUSLABS

Pharma

₹1969.00

price as of 11/9/2026, 5:28:15 pm

Market cap ₹1.06 L Cr

P/E: 97.33
Day range: ₹1,918.10 – ₹1,981.80
52-week range: ₹823.10 – ₹1,981.80
Volume: 22.77 L
Open: ₹1,943.00
Prev close: ₹1,945.00

Promoters pledged 23.2% of their shares

52-week range, adjusted for splits and bonuses

₹823.1

₹1,955

26 Sept 20259 Sept 2026

Index membership & F&O

NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCARENIFTY PHARMAF&O lot 850

Price history

6M change +89.15%RSI (14) 67.8 NeutralSMA 20 · 50 overlaid

Price & delivery on the exchange

NSE bhavcopy to 11 Sept 2026 · delivery 47.0% today vs 51.1% average · BSE close ₹1,970.35

Delivery
NSE close
BSE close

High delivery with a rising price suggests buyers holding rather than trading the move.

Futures & options

NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

Long build-up

Near-month future: ₹1,978.8
Change: +1.68%
Basis over spot: +₹9.80
Futures OI (shares): 1.76 Cr
OI change: +0.91%
Put-call ratio: 0.69
Max pain: ₹1,880
Resistance (call OI): ₹2,000
Support (put OI): ₹1,800
Lot size: 850

Open interest by strike

Calls open above (resistance) and puts below (support), in shares

Call OI
Put OI

Futures open interest and price

Near-month future, day by day since collection began

The daily history builds from each close.

Key metrics

P/E (TTM): 96.1
EPS (TTM): ₹20.23
ROE (FY26): 18.2%
ROCE (latest year): 18%
Dividend yield: 0.10%

Charts & trends

From company filings. Amounts in ₹ crore.

Revenue 3Y CAGR

+4.1%

Profit 3Y CAGR

+3.9%

Revenue YoY (Jun 2026)

+29.0%

Profit YoY (Jun 2026)

+123.5%

Operating margin

32.0%

Net margin

17.9%

Revenue, profit & margin - quarterly

Bars in ₹ crore (a loss shows red); line is operating margin

Revenue
Net profit
Operating margin

Who owns the company

Shareholding as of Jun 2026

Public
FII
Promoter
DII

Cash flows

Where cash came from and went, by fiscal year (₹ crore)

Operating
Investing
Financing
Free cash flow

Return on equity

Net profit over shareholders' equity, by fiscal year

Equity vs debt

Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

Equity
Debt
Debt / equity

Financial statements

₹ Crore

Quarterly results, oldest period first, figures in rupees crore
Line item	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,224	1,195	1,440	1,195	1,224	1,415	1,720	1,570	1,653	1,778	1,812	2,026
Expenses	1,037	1,014	1,198	1,024	1,045	1,130	1,300	1,187	1,250	1,298	1,299	1,388
Operating Profit	188	181	241	171	178	285	421	382	403	480	512	638
OPM %	15%	15%	17%	14%	15%	20%	24%	24%	24%	27%	28%	32%
Other Income	2	2	19	3	5	9	59	10	27	6	12	9
Interest	42	51	50	49	53	58	56	52	40	39	40	42
Depreciation	93	98	102	106	108	106	110	117	120	121	122	124
Profit before tax	54	35	107	18	23	131	312	224	270	327	361	481
Tax %	27%	27%	30%	34%	22%	31%	25%	28%	28%	22%	22%	25%
Net Profit	37	23	75	13	20	93	233	162	194	252	282	362
EPS in Rs	₹0.69	₹0.43	₹1.40	₹0.23	₹0.37	₹1.71	₹4.33	₹3.02	₹3.61	₹4.66	₹5.17	₹6.80

From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

Strengths, risks & growth

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Strengths

Company has been maintaining a healthy dividend payout of 19.0%

Risks

Stock is trading at 20.1 times its book value
The company has delivered a poor sales growth of 7.19% over past five years.
Company has a low return on equity of 10.1% over last 3 years.
Company might be capitalizing the interest cost

Compounded Sales Growth

10 Years: +14%
5 Years: +7%
3 Years: +4%
TTM: +23%

Compounded Profit Growth

10 Years: +21%
5 Years: -2%
3 Years: +4%
TTM: +115%

Stock Price CAGR

10 Years: —
5 Years: +25%
3 Years: +72%
1 Year: +120%

Return on Equity

10 Years: +17%
5 Years: +15%
3 Years: +10%
Last Year: +18%

Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

Shareholding pattern

Percentage of shares held by each category at each quarter end
Holder	Sept 2025	Dec 2025	Mar 2026	Jun 2026	Change
Promoter	27.60%	27.49%	27.49%	27.47%	-0.02 pp
FII	26.17%	26.52%	25.82%	28.00%	+2.18 pp
DII	11.72%	12.42%	13.96%	13.73%	-0.23 pp
Public	34.52%	33.57%	32.73%	30.79%	-1.94 pp

Filed with NSE for Jun 2026: promoters 27.47%, public 72.53% · XBRL filing

Analysts & fund holdings

58% recommend buy

12 analysts cover the stock

Valuation vs Pharmaceuticals

P/E97.3 vs 46.4

Sector P/B5.84

Beta0.98

Who holds the shares, quarter by quarter

Mutual funds 10.15% (-1.07 pp)

Mar 25

Jun 25

Sept 25

Dec 25

Mar 26

Jun 26

Promoters27.5%
Foreign institutions28.0%
Mutual funds10.2%
Insurance2.3%
Other domestic institutions1.3%
Retail12.6%
Others18.1%

Mutual funds holding the most
Fund	% of company	% of fund	3-month change
Mirae Asset Large & Midcap Fund	1.75%	3.72%	+1.29 pp
Mirae Asset ELSS Tax Saver Fund	1.24%	4.56%	+1.45 pp
Mirae Asset Midcap Fund	0.88%	4.12%	+1.24 pp
UTI Nifty200 Momentum 30 Index Fund	0.52%	5.95%	+1.17 pp
SBI Healthcare Opp Fund	0.24%	3.96%	+0.32 pp

Scorecard

Performance: High
Valuation: High
Growth: Low
Profitability: High
Entry point: Avg
Red flags: Low

Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

Corporate actions

dividend
₹1.20
Interim Dividend - Rs 1.20 Per Share
8 May 2026
ex-date
dividend
Not available — not reported in this filing
Interim Dividend - Re 0.80 Per Sh
31 Oct 2025
ex-date
dividend
₹0.80
Interim Dividend - Rs 0.80 Per Share
9 May 2025
ex-date
dividend
₹0.40
Interim Dividend - Rs 0.40 Per Share
6 Nov 2024
ex-date
other
Not available — not reported in this filing
Annual General Meeting
4 Jul 2024
ex-date
dividend
Not available — not reported in this filing
Interim Dividend - Re 0.40 Per Share
8 May 2024
ex-date
dividend
Not available — not reported in this filing
Interim Dividend - Re 0.40 Per Share
2 Nov 2023
ex-date
other
Not available — not reported in this filing
Annual General Meeting
7 Jul 2023
ex-date
dividend
₹1.20
Interim Dividend - Rs 1.20 Per Share
10 May 2023
ex-date
dividend
₹0.80
Interim Dividend - Rs 0.80 Per Share
3 Nov 2022
ex-date
other
Not available — not reported in this filing
Annual General Meeting
22 Jun 2022
ex-date
dividend
₹1.20
Interim Dividend - Rs 1.20 Per Share
10 May 2022
ex-date
dividend
₹0.80
Interim Dividend - Rs 0.80 Per Share
17 Nov 2021
ex-date
other
Not available — not reported in this filing
Annual General Meeting
7 Jul 2021
ex-date
dividend
Not available — not reported in this filing
Interim Dividend - Re 0.80 Per Share
11 May 2021
ex-date
dividend
₹0.40
Interim Dividend - Rs 0.40 Per Share
8 Feb 2021
ex-date
dividend
₹0.80
Interim Dividend - Rs 0.80 Per Share
10 Nov 2020
ex-date
split
Not available — not reported in this filing
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share
29 Sept 2020
ex-date
dividend
Not available — not reported in this filing
Annual General Meeting/Dividend - Re 1 Per Share
1 Jul 2020
ex-date
dividend
₹1.50
Interim Dividend - Rs 1.50 Per Share
23 Mar 2020
ex-date